See more : Ascension Capital Limited (ACE.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Gilead Sciences, Inc. (GILD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gilead Sciences, Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- AF Gruppen ASA (AGRUF) Income Statement Analysis – Financial Results
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Income Statement Analysis – Financial Results
- Calibre Mining Corp. (CXBMF) Income Statement Analysis – Financial Results
- IIFL Securities Limited (IIFLSEC.BO) Income Statement Analysis – Financial Results
- HORNG TERNG (7751.TWO) Income Statement Analysis – Financial Results
Gilead Sciences, Inc. (GILD)
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.12B | 27.28B | 27.31B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B | 32.64B | 24.89B | 11.20B | 9.70B | 8.39B | 7.95B | 7.01B | 5.34B | 4.23B | 3.03B | 2.03B | 1.32B | 867.86M | 466.79M | 233.77M | 195.56M | 169.00M | 32.60M | 40.00M | 33.40M | 2.70M | 4.10M | 4.20M | 2.80M | 1.30M |
| Cost of Revenue | 6.50B | 5.66B | 6.60B | 4.57B | 4.68B | 4.85B | 4.37B | 4.26B | 4.01B | 3.79B | 2.86B | 2.47B | 2.12B | 1.87B | 1.60B | 1.13B | 768.77M | 433.32M | 260.33M | 166.59M | 112.69M | 69.72M | 43.76M | 21.50M | 16.90M | -2.20M | -1.80M | -3.60M | -3.20M | -2.80M | -1.70M | -1.00M | -800.00K |
| Gross Profit | 20.62B | 21.62B | 20.70B | 20.12B | 17.77B | 17.27B | 21.74B | 26.13B | 28.63B | 21.10B | 8.34B | 7.23B | 6.26B | 6.08B | 5.42B | 4.21B | 3.46B | 2.59B | 1.77B | 1.16B | 755.17M | 397.07M | 190.01M | 174.05M | 152.10M | 34.80M | 41.80M | 37.00M | 5.90M | 6.90M | 5.90M | 3.80M | 2.10M |
| Gross Profit Ratio | 76.04% | 79.26% | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% | 85.98% | 87.73% | 84.78% | 74.48% | 74.53% | 74.67% | 76.48% | 77.24% | 78.87% | 81.83% | 85.68% | 87.17% | 87.42% | 87.02% | 85.06% | 81.28% | 89.00% | 90.00% | 106.75% | 104.50% | 110.78% | 218.52% | 168.29% | 140.48% | 135.71% | 161.54% |
| Research & Development | 6.92B | 4.98B | 5.36B | 5.04B | 9.11B | 5.02B | 3.73B | 5.10B | 3.01B | 2.85B | 2.12B | 1.76B | 1.23B | 1.07B | 939.92M | 721.77M | 591.03M | 383.86M | 277.72M | 223.55M | 164.87M | 134.76M | 185.55M | 131.57M | 112.90M | 75.30M | 59.20M | 41.90M | 0.00 | 26.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.26B | 4.90B | 4.51B | 4.36B | 3.60B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 826.00M | 778.00M | 735.00M | 795.00M | 784.00M | 587.00M | 600.00M | 618.00M | 601.00M | 393.00M | 216.00M | 160.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.09B | 5.67B | 5.25B | 5.15B | 4.38B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 34.70M | 7.60M | 22.40M | 9.10M | 6.10M |
| Other Expenses | 0.00 | -581.00M | -639.00M | -1.42B | 1.87B | 676.00M | 523.00M | 428.00M | 154.00M | 3.00M | -8.89M | -37.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.22M | 0.00 | 0.00 | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| Operating Expenses | 13.67B | 10.65B | 10.61B | 10.19B | 13.49B | 9.07B | 7.61B | 8.50B | 6.44B | 5.84B | 3.82B | 3.22B | 2.47B | 2.12B | 1.89B | 1.53B | 1.30B | 957.52M | 656.97M | 526.35M | 425.25M | 316.06M | 310.69M | 226.37M | 203.80M | 109.10M | 87.70M | 73.10M | 37.90M | 36.40M | 24.10M | 10.10M | 6.90M |
| Cost & Expenses | 19.69B | 16.31B | 17.21B | 14.76B | 18.16B | 13.93B | 11.98B | 12.76B | 10.45B | 9.63B | 6.68B | 5.69B | 4.60B | 3.99B | 3.48B | 2.66B | 2.07B | 1.39B | 917.30M | 692.93M | 537.94M | 385.78M | 354.46M | 247.87M | 220.70M | 106.90M | 85.90M | 69.50M | 34.70M | 33.60M | 22.40M | 9.10M | 6.10M |
| Interest Income | 0.00 | 935.00M | 1.00B | 984.00M | 995.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.58M | 60.29M | 42.40M | 59.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 944.00M | 935.00M | 1.00B | 984.00M | 995.00M | 1.08B | 1.12B | 964.00M | 688.00M | 412.00M | 306.89M | 360.92M | 205.42M | 108.96M | 69.66M | 12.10M | 0.00 | 4.67B | 0.00 | 0.00 | 996.28M | 23.66M | 0.00 | 6.12M | 37.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.69B | 2.10B | 2.05B | 1.48B | 1.40B | 1.43B | 1.29B | 1.16B | 1.10B | 1.05B | 344.70M | 278.21M | 302.23M | 265.48M | 212.94M | 102.47M | 51.28M | 47.28M | 35.78M | 24.41M | 20.86M | 14.43M | 14.69M | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| EBITDA | 10.50B | 8.85B | 11.33B | 4.13B | 7.56B | 10.31B | 15.93B | 19.22B | 23.45B | 16.32B | 4.86B | 4.25B | 4.16B | 4.29B | 3.78B | 2.84B | 2.22B | -576.83M | 1.15B | 688.18M | 350.78M | 81.01M | -106.00M | -40.31M | -39.10M | -65.10M | -56.90M | -31.60M | -28.80M | -31.30M | -16.50M | -5.30M | -4.00M |
| EBITDA Ratio | 38.71% | 38.10% | 34.63% | 34.46% | 27.42% | 40.11% | 56.10% | 59.43% | 68.47% | 61.34% | 40.31% | 40.95% | 45.99% | 50.60% | 50.94% | 51.47% | 52.38% | 134.71% | 56.54% | 48.54% | 97.90% | 23.88% | -116.58% | -19.15% | -9.05% | -275.77% | -153.00% | -139.52% | -1,259.26% | -753.66% | -495.24% | -257.14% | -369.23% |
| Operating Income | 7.61B | 7.33B | 7.41B | 7.03B | 4.29B | 8.20B | 14.12B | 17.63B | 22.19B | 15.27B | 4.52B | 4.01B | 3.79B | 3.96B | 3.53B | 2.68B | 2.16B | -758.75M | 1.11B | 631.69M | -158.68M | 81.01M | -120.69M | -52.32M | -51.70M | -74.30M | -45.90M | -36.10M | -32.00M | -29.50M | -18.20M | -6.30M | -4.80M |
| Operating Income Ratio | 28.05% | 26.87% | 27.12% | 28.47% | 19.10% | 37.06% | 54.10% | 58.02% | 68.00% | 61.33% | 40.39% | 41.33% | 45.20% | 49.84% | 50.34% | 50.20% | 51.17% | -25.07% | 54.78% | 47.69% | -18.28% | 17.35% | -51.63% | -26.75% | -30.59% | -227.91% | -114.75% | -108.08% | -1,185.19% | -719.51% | -433.33% | -225.00% | -369.23% |
| Total Other Income/Expenses | -746.00M | -1.52B | 872.00M | -2.40B | 873.00M | -401.00M | -595.00M | -536.00M | -534.00M | -409.00M | -315.78M | -398.20M | -138.84M | -48.67M | -27.27M | -5.84M | 105.83M | 120.55M | 50.69M | 24.73M | -8.86M | -7.61M | 178.14M | 10.41M | -13.90M | 22.40M | -500.00K | 15.00M | 5.20M | 9.90M | 4.30M | 1.90M | 800.00K |
| Income Before Tax | 6.86B | 5.81B | 8.28B | 1.67B | 5.16B | 7.80B | 13.53B | 17.10B | 21.66B | 14.86B | 4.21B | 3.61B | 3.65B | 3.91B | 3.50B | 2.73B | 2.27B | -638.21M | 1.16B | 656.42M | -167.53M | 73.40M | 57.45M | -41.91M | -65.60M | -55.90M | -27.60M | -21.10M | -26.80M | -25.30M | -13.90M | -4.40M | -4.00M |
| Income Before Tax Ratio | 25.30% | 21.31% | 30.32% | 6.76% | 22.99% | 35.25% | 51.82% | 56.26% | 66.36% | 59.69% | 37.57% | 37.23% | 43.54% | 49.23% | 49.95% | 51.25% | 53.67% | -21.09% | 57.28% | 49.56% | -19.30% | 15.72% | 24.57% | -21.43% | -38.82% | -171.47% | -69.00% | -63.17% | -992.59% | -617.07% | -330.95% | -157.14% | -307.69% |
| Income Tax Expense | 1.25B | 1.25B | 2.08B | 1.58B | -204.00M | 2.34B | 8.89B | 3.61B | 3.55B | 2.80B | 1.15B | 1.04B | 861.95M | 1.02B | 876.36M | 723.25M | 655.04M | 551.75M | 347.88M | 207.05M | -95.53M | 1.30M | 4.14M | 1.20M | 900.00K | -36.60M | -36.20M | -29.40M | -9.80M | -8.00M | -8.40M | -3.70M | -1.60M |
| Net Income | 5.67B | 4.59B | 6.23B | 89.00M | 5.39B | 5.46B | 4.63B | 13.50B | 18.11B | 12.10B | 3.07B | 2.59B | 2.80B | 2.90B | 2.64B | 2.01B | 1.62B | -1.19B | 813.91M | 449.37M | -72.00M | 72.10M | 52.27M | -56.78M | -66.50M | -56.10M | -28.00M | -21.70M | -27.40M | -25.70M | -14.10M | -4.50M | -4.00M |
| Net Income Ratio | 20.89% | 16.83% | 22.80% | 0.36% | 23.99% | 24.65% | 17.73% | 44.43% | 55.48% | 48.62% | 27.45% | 26.71% | 33.43% | 36.50% | 37.59% | 37.69% | 38.19% | -39.32% | 40.13% | 33.92% | -8.30% | 15.45% | 22.36% | -29.03% | -39.35% | -172.09% | -70.00% | -64.97% | -1,014.81% | -626.83% | -335.71% | -160.71% | -307.69% |
| EPS | 4.54 | 3.66 | 4.96 | 0.07 | 4.24 | 4.20 | 3.54 | 10.08 | 12.37 | 7.95 | 2.01 | 1.71 | 1.81 | 1.70 | 1.46 | 1.09 | 0.87 | -0.65 | 0.45 | 0.26 | -0.04 | 0.05 | 0.04 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | 4.50 | 3.64 | 4.93 | 0.07 | 4.22 | 4.17 | 3.51 | 9.94 | 11.91 | 7.35 | 1.81 | 1.64 | 1.78 | 1.66 | 1.41 | 1.05 | 0.84 | -0.65 | 0.43 | 0.25 | -0.04 | 0.04 | 0.03 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.25B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B | 1.46B | 1.52B | 1.53B | 1.51B | 1.55B | 1.71B | 1.81B | 1.84B | 1.86B | 1.84B | 1.82B | 1.73B | 1.61B | 1.56B | 1.52B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B | 1.52B | 1.65B | 1.69B | 1.58B | 1.58B | 1.75B | 1.87B | 1.92B | 1.93B | 1.84B | 1.90B | 1.86B | 1.61B | 1.65B | 1.62B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted population.
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and...
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
Gilead Sciences (GILD) reachead $85.21 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
Gilead's lenacapavir may become a blockbuster HIV prophylactic. Biktarvy maintains a dominant market share in the HIV treatment space, contributing significantly to Gilead's revenue growth. Gilead's oncology segment is expanding, with Trodelvy and Yescarta showing potential for accelerated revenue growth.
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda
Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus disease outbreak.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
- Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India , Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest...
Source: https://incomestatements.info
Category: Stock Reports